

2001, if the problem(s) is not corrected, you must reject the test and report the result in accordance with § 40.97(a)(3).

(h) If the CCF is marked indicating that a split specimen collection was collected and if the split specimen does not accompany the primary, has leaked, or is otherwise unavailable for testing, you must still test the primary specimen and follow appropriate procedures outlined in § 40.175(b) regarding the unavailability of the split specimen for testing.

(1) The primary specimen and the split specimen can be redesignated (*i.e.*, Bottle B is redesignated as Bottle A, and vice-versa) if:

(i) The primary specimen appears to have leaked out of its sealed bottle and the laboratory believes a sufficient amount of urine exists in the split specimen to conduct all appropriate primary laboratory testing; or

(ii) The primary specimen is labeled as Bottle B, and the split specimen as Bottle A; or

(iii) The laboratory opens the split specimen instead of the primary specimen, the primary specimen remains sealed, and the laboratory believes a sufficient amount of urine exists in the split specimen to conduct all appropriate primary laboratory testing; or

(iv) The primary specimen seal is broken but the split specimen remains sealed and the laboratory believes a sufficient amount of urine exists in the split specimen to conduct all appropriate primary laboratory testing.

(2) In situations outlined in paragraph (g)(1) of this section, the laboratory shall mark through the “A” and write “B,” then initial and date the change. A corresponding change shall be made to the other bottle by marking through the “B” and writing “A,” and initialing and dating the change.

(i) A notation shall be made on Copy 1 of the CCF (Step 5a) and on any laboratory internal chain of custody documents, as appropriate, for any fatal or correctable flaw.

[65 FR 79526, Dec. 19, 2000, as amended at 66 FR 41951, Aug. 9, 2001]

§ 40.85 What drugs do laboratories test for?

As a laboratory, you must test for the following five drugs or classes of drugs in a DOT drug test. You must not test “DOT specimens” for any other drugs.

- (a) Marijuana metabolites.
- (b) Cocaine metabolites.
- (c) Amphetamines.
- (d) Opiate metabolites.
- (e) Phencyclidine (PCP).

§ 40.87 What are the cutoff concentrations for initial and confirmation tests?

(a) As a laboratory, you must use the cutoff concentrations displayed in the following table for initial and confirmation drug tests. All cutoff concentrations are expressed in nanograms per milliliter (ng/mL). The table follows:

| Type of drug or metabolite | Initial test | Confirmation test |
|-----------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| (1) Marijuana metabolites | 50 | 15 |
| (i) Delta-9-tetrahydrocanna-binol-9-carboxylic acid (THC) | | |
| (2) Cocaine metabolites (Benzoylcegonine) | 300 | 150 |
| (3) Phencyclidine (PCP) | 25 | 25 |
| (4) Amphetamines | 1000 | 500 |
| (i) Amphetamine | | 500 (Specimen must also contain amphetamine at a concentration of greater than or equal to 200 ng/mL.) |
| (ii) Methamphetamine | | |
| (5) Opiate metabolites | 2000 | 2000 |
| (i) Codeine | | 2000 |
| (ii) Morphine | | 10 (Test for 6-AM in the specimen. Conduct this test only when specimen contains morphine at a concentration greater than or equal to 2000 ng/mL.) |
| (iii) 6-acetylmorphine (6-AM) | | |

(b) On an initial drug test, you must report a result below the cutoff concentration as negative. If the result is

at or above the cutoff concentration, you must conduct a confirmation test.